Results 51 to 60 of about 189,087 (191)

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. [PDF]

open access: yes, 2017
The purpose of our study was to investigate the two-year outcome of Aflibercept treatment for neovascular age-related macular degeneration (nAMD), using the Observe-and-Plan regimen, an individually planned treatment regimen, based on the predictability ...
Ambresin, A.   +4 more
core   +1 more source

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration

open access: yesРоссийский офтальмологический журнал, 2020
Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenesis inhibitors in the treat-and-extend regimen in patients with the “wet” form of age-related macular degeneration (wAMD). Materials and methods.
S. V. Nedogoda   +5 more
doaj   +1 more source

Effect of Intravitreous Anti–Vascular Endothelial Growth Factor Therapy on Choroidal Thickness in Neovascular Age-Related Macular Degeneration Using Spectral-Domain Optical Coherence Tomography [PDF]

open access: yes, 2013
A critical method of monitoring patients with neovascular age-related macular degeneration (AMD) being treated with anti–vascular endothelial growth factor (anti-VEGF) is optical coherence tomography (OCT), which uses low-coherence interferometry of ...
Adhi, Mehreen   +6 more
core   +1 more source

Patient satisfaction following a switch from treat-and- extend to observe-and-plan regimen in age-related macular degeneration [PDF]

open access: yes, 2022
Objective Standard treatment of neovascular age-related macular degeneration (nAMD) is intravitreal injections (IVI) of antivascular endothelial growth factor (anti-VEGF) according to treat-and-extend (TnE). Observe-and-plan (OnP), a new regimen based on
Austeng, Dordi   +3 more
core   +1 more source

Ranibizumab For Diabetic Macular Edema Refractory To Multiple Prior Treatments [PDF]

open access: yes, 2016
Purpose: Diabetic macular edema can be refractory to multiple treatment modalities. Although there have been anecdotal reports of ranibizumab showing efficacy when other modalities provided limited benefit, little has been published on treatment for ...
Ciulla, Lauren   +4 more
core   +2 more sources

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration [PDF]

open access: yes, 2021
PURPOSE: Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as treatment of neovascular age-related macular degeneration (nAMD), the (economic) burden on the healthcare system is considerable. A treat-and-extend (T&E)
de Jong, L. A.   +5 more
core   +1 more source

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan

open access: yesBMC Ophthalmology, 2022
The management of neovascular age-related macular degeneration (nAMD) has taken a major stride forward with the advent of anti-VEGF agents. The treat-and-extend (T&E) approach is a refined management strategy, tailoring to the individual patient’s ...
Cheng-Kuo Cheng   +15 more
doaj   +1 more source

Myasthenia Gravis with Membranous Nephropathy, Successfully Treated with Extended Total Thymectomy.

open access: yesInternal Medicine, 2000
A 46-year-old woman showed proteinuria and hematuria after left blepharoptosis, and revealed a histopathology of membranous nephropathy (MN) at renal biopsy. She was diagnosed as having myasthenia gravis (MG) because of a positive edrophonium test and anti-acetylcholine receptor (AchR) antibodies in serum.
M, Matsuda   +5 more
openaire   +3 more sources

Treatment Strategies for Refractory Diabetic Macular Edema: Switching Anti-VEGF Treatments, adopting corticosteroid-based treatments, and combination therapy [PDF]

open access: yes, 2016
Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators.
Ciulla, Thomas A., Hussain, Rehan M.
core   +1 more source

Treat & extend versus PRN in AMD

open access: yesActa Ophthalmologica, 2016
SummaryBasically 3 different approaches to anti‐VEGF treatment in AMD are in clinical use, a fixed regimen using monthly or bi‐monthly injections (IVI), a PRN strategy and a Treat and Extend (T&E) regimen.T&E is a proactive and individualized anti‐VEGF treatment regimen. Basically IVI are performed monthly until stability is achieved.
openaire   +1 more source

Home - About - Disclaimer - Privacy